Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 18/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.74 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.74 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.68 |
| ▸ | MPO | P05164 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29936348 | 1.00 | GRIK1 (1.00) | GRIK1MEN1KMT2ANTRK1CDK19 | |
| SCHEMBL5464394 | 0.90 | GRIK1 (0.82) | GRIK1MEN1KMT2ANTRK1CDK19 | |
| SCHEMBL1463123 | 0.90 | GRIK1 (1.00) | GRIK1MEN1KMT2ANTRK1CDK19 | |
| SCHEMBL1463260 | 0.89 | GRIK1 (0.81) | GRIK1MEN1KMT2A | |
| SCHEMBL6430905 | 0.86 | GRIK1 (1.00) | GRIK1MEN1KMT2AGRIK2 | |
| SCHEMBL10385394 | 0.86 | MPO (0.81) | GRIK1MEN1KMT2ANTRK1CDK19 | |
| SCHEMBL5597796 | 0.86 | NTRK1 (0.79) | GRIK1MEN1KMT2ANTRK1CDK19 | |
| SCHEMBL29835007 | 0.86 | MPO (0.81) | GRIK1MEN1KMT2ANTRK1CDK19 | |
| SCHEMBL3961840 | 0.86 | GRIK1 (1.00) | GRIK1MEN1KMT2AGRIK2 | |
| SCHEMBL6435235 | 0.85 | GRIK1 (1.00) | GRIK1MEN1KMT2ANTRK1CDK19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3946437-B1 | EX VIVO METHODS FOR PRODUCING A T CELL THERAPEUTIC AND RELATED COMPOSITIONS AND METHODS | H LEE MOFFITT CANCER CT & RES (US) | 2025-11-19 | — | — | EP | claimed |
| EP-4361256-A2 | MEDIA AND METHODS FOR ENHANCING THE SURVIVAL AND PROLIFERATION OF STEM CELLS | Stemcell Technologies Canada Inc. (CA) | 2024-05-01 | — | — | EP | claimed |
| EP-3571290-B1 | MEDIA AND METHODS FOR ENHANCING THE SURVIVAL AND PROLIFERATION OF STEM CELLS | STEMCELL TECHNOLOGIES CANADA INC (CA) | 2024-04-10 | — | — | EP | claimed |
| US-20240000935-A1 | ANTIGEN SPECIFIC T CELLS AND METHODS OF MAKING AND USING SAME | GENEIUS BIOTECHNOLOGY, INC. (US) | 2024-01-04 | — | — | US | claimed |
| CN-110462025-B | Media and methods for enhancing stem cell survival and proliferation | 加拿大干细胞技术公司 | 2023-11-21 | — | — | CN | claimed |
| EP-4251177-A2 | ANTIGEN SPECIFIC T CELLS AND METHODS OF MAKING AND USING SAME | Geneius Biotechnology, Inc. (US) | 2023-10-04 | — | — | EP | claimed |
| US-11697796-B2 | Media and methods for enhancing the survival and proliferation of stem cells | STEMCELL TECHNOLOGIES CANADA INC. (CA) | 2023-07-11 | — | — | US | claimed |
| US-20230032934-A1 | METHOD OF PRODUCING TUMOR-REACTIVE T CELL COMPOSITION USING MODULATORY AGENTS | MYST THERAPEUTICS, LLC (US) | 2023-02-02 | — | — | US | claimed |
| EP-4110799-A1 | METHODS FOR EX VIVO ENRICHMENT AND EXPANSION OF TUMOR REACTIVE T CELLS AND RELATED COMPOSITIONS THEREOF | Myst Therapeutics, LLC (US) | 2023-01-04 | — | — | EP | claimed |
| CN-115427438-A | Methods for ex vivo enrichment and expansion of tumor-reactive T cells and compositions related thereto | 迈斯特治疗公司 | 2022-12-02 | — | — | CN | claimed |
| EP-4065229-A1 | METHOD OF PRODUCING TUMOR-REACTIVE T CELL COMPOSITION USING MODULATORY AGENTS | Myst Therapeutics, LLC (US) | 2022-10-05 | — | — | EP | claimed |
| US-20220177841-A1 | EX VIVO METHODS FOR PRODUCING A T CELL THERAPEUTIC AND RELATED COMPOSITIONS AND METHODS | MYST THERAPEUTICS LLC (US) | 2022-06-09 | — | — | US | claimed |
| WO-2022115641-A2 | ANTIGEN SPECIFIC T CELLS AND METHODS OF MAKING AND USING SAME | GENEIUS BIOTECHNOLOGY, INC. (US) | 2022-06-02 | — | — | WO | claimed |
| EP-3946437-A1 | EX VIVO METHODS FOR PRODUCING A T CELL THERAPEUTIC AND RELATED COMPOSITIONS AND METHODS | Myst Therapeutics, LLC (US) | 2022-02-09 | — | — | EP | claimed |
| US-20060069255-A1 | Novel aryl ureido benzoic acid derivatives and their use | NEUROSEARCH (DK) | 2006-03-30 | — | — | US | claimed |
| EP-1565429-A2 | ARYL UREIDO DERIVATIVES AND THEIR MEDICAL USE | NEUROSEARCH A/S (DK) | 2005-08-24 | — | — | EP | claimed |
| US-20050080112-A1 | Compounds for use in disorders associated with mast cell or basophil acitvity | POSEIDON PHARMACEUTICALS A/S (DK) | 2005-04-14 | — | — | US | claimed |
| WO-2004046090-A2 | ARYL UREIDO DERIVATIVES AND THEIR MEDICAL USE | NEUROSEARCH A/S (DK) | 2004-06-03 | — | — | WO | claimed |
| US-20040077634-A1 | Treatment of diseases characterized by excessive or insufficient cell death | NEUROSEARCH A/S (DK) | 2004-04-22 | — | — | US | claimed |
| EP-4743560-A1 | ALTERNATING RECIRCULATING TANGENTIAL FLOW (ARTF) FILTRATION FOR CELL CULTURE MEDIA PERFUSION AND BIOREACTOR HARVESTING | AMGEN INC. (US) | 2026-05-20 | — | — | EP | disclosed |
| WO-2026044087-A1 | INCREASED CELLULAR STABILITY FOR AAV PRODUCTION | SHAPE THERAPEUTICS INC. (US) | 2026-02-26 | — | — | WO | disclosed |
| EP-3946437-B1 | EX VIVO METHODS FOR PRODUCING A T CELL THERAPEUTIC AND RELATED COMPOSITIONS AND METHODS | H LEE MOFFITT CANCER CT & RES (US) | 2025-11-19 | — | — | EP | disclosed |
| US-20250312353-A1 | DRUG REPURPOSING FOR TREATMENT OF CONGENITAL VASCULAR MALFORMATIONS | UNIVERSITY OF SOUTH CAROLINA (US) | 2025-10-09 | — | — | US | disclosed |
| EP-4512828-A2 | METHODS FOR EX VIVO ENRICHMENT AND EXPANSION OF TUMOR REACTIVE T CELLS AND RELATED COMPOSITIONS THEREOF | Turnstone Biologics Corp. (US) | 2025-02-26 | — | — | EP | disclosed |
| WO-2025015044-A1 | ALTERNATING RECIRCULATING TANGENTIAL FLOW (ARTF) FILTRATION FOR CELL CULTURE MEDIA PERFUSION AND BIOREACTOR HARVESTING | AMGEN INC. (US) | 2025-01-16 | — | — | WO | disclosed |
| US-12195779-B2 | Methods for harvesting mammalian cell cultures | AMGEN INC. (US) | 2025-01-14 | — | — | US | disclosed |
| US-12171821-B2 | Toxoplasma gondii vaccine | WISCONSIN ALUMNI RESEARCH FOUNDATION (WARF) (US) | 2024-12-24 | — | — | US | disclosed |
| US-20240417685-A1 | METHODS FOR EX VIVO ENRICHMENT AND EXPANSION OF TUMOR REACTIVE T CELLS AND RELATED COMPOSITIONS THEREOF | MYST THERAPEUTICS, LLC (US) | 2024-12-19 | — | — | US | disclosed |
| EP-4110799-B1 | METHODS FOR EX VIVO ENRICHMENT AND EXPANSION OF TUMOR REACTIVE T CELLS AND RELATED COMPOSITIONS THEREOF | TURNSTONE BIOLOGICS CORP (US) | 2024-11-06 | — | — | EP | disclosed |
| US-12133720-B2 | Methods and compositions for restoring homeostatic capacity of a subject | Palo Alto Investors LP (US) | 2024-11-05 | — | — | US | disclosed |
| EP-4372078-A2 | METHODS FOR HARVESTING MAMMALIAN CELL CULTURES | Amgen Inc. (US) | 2024-05-22 | — | — | EP | disclosed |
| EP-4361256-A2 | MEDIA AND METHODS FOR ENHANCING THE SURVIVAL AND PROLIFERATION OF STEM CELLS | Stemcell Technologies Canada Inc. (CA) | 2024-05-01 | — | — | EP | disclosed |
| EP-3571290-B1 | MEDIA AND METHODS FOR ENHANCING THE SURVIVAL AND PROLIFERATION OF STEM CELLS | STEMCELL TECHNOLOGIES CANADA INC (CA) | 2024-04-10 | — | — | EP | disclosed |
| US-20240000935-A1 | ANTIGEN SPECIFIC T CELLS AND METHODS OF MAKING AND USING SAME | GENEIUS BIOTECHNOLOGY, INC. (US) | 2024-01-04 | — | — | US | disclosed |
| CN-110462025-B | Media and methods for enhancing stem cell survival and proliferation | 加拿大干细胞技术公司 | 2023-11-21 | — | — | CN | disclosed |
| EP-4251177-A2 | ANTIGEN SPECIFIC T CELLS AND METHODS OF MAKING AND USING SAME | Geneius Biotechnology, Inc. (US) | 2023-10-04 | — | — | EP | disclosed |
| US-20230287335-A1 | CELL CULTURE MEDIA AND METHODS OF MAKING AND USING THE SAME | AMGEN INC. | 2023-09-14 | — | — | US | disclosed |
| US-20230250392-A1 | MEDIA AND METHODS FOR ENHANCING THE SURVIVAL AND PROLIFERATION OF STEM CELLS | STEMCELL TECHNOLOGIES CANADA INC. (CA) | 2023-08-10 | — | — | US | disclosed |
| US-11697796-B2 | Media and methods for enhancing the survival and proliferation of stem cells | STEMCELL TECHNOLOGIES CANADA INC. (CA) | 2023-07-11 | — | — | US | disclosed |
| EP-4189064-A1 | CELL CULTURE MEDIA AND METHODS OF MAKING AND USING THE SAME | Amgen Inc. (US) | 2023-06-07 | — | — | EP | disclosed |
| US-20230032934-A1 | METHOD OF PRODUCING TUMOR-REACTIVE T CELL COMPOSITION USING MODULATORY AGENTS | MYST THERAPEUTICS, LLC (US) | 2023-02-02 | — | — | US | disclosed |
| EP-4110799-A1 | METHODS FOR EX VIVO ENRICHMENT AND EXPANSION OF TUMOR REACTIVE T CELLS AND RELATED COMPOSITIONS THEREOF | Myst Therapeutics, LLC (US) | 2023-01-04 | — | — | EP | disclosed |
| CN-115427438-A | Methods for ex vivo enrichment and expansion of tumor-reactive T cells and compositions related thereto | 迈斯特治疗公司 | 2022-12-02 | — | — | CN | disclosed |
| US-20220356502-A1 | METHODS FOR HARVESTING MAMMALIAN CELL CULTURES | AMGEN INC. (US) | 2022-11-10 | — | — | US | disclosed |
| EP-4065229-A1 | METHOD OF PRODUCING TUMOR-REACTIVE T CELL COMPOSITION USING MODULATORY AGENTS | Myst Therapeutics, LLC (US) | 2022-10-05 | — | — | EP | disclosed |
| WO-2022190064-A1 | METHODS FOR IDENTIFYING SUBJECTS WITH BETACORONAVIRUS INFECTIONS WHO ARE AT RISK OF ACUTE RESPIRATORY SYNDROME AND METHODS FOR THE TREATMENT OF SAME | VEXO PHARMACEUTICALS DMCC (AE) | 2022-09-15 | — | — | WO | disclosed |
| CN-115023270-A | Methods of generating tumor-reactive T cell compositions using modulators | 迈斯特治疗公司 | 2022-09-06 | — | — | CN | disclosed |
| US-11427848-B2 | Methods for harvesting mammalian cell cultures | AMGEN INC. (US) | 2022-08-30 | — | — | US | disclosed |
| US-11384378-B2 | Methods for harvesting mammalian cell cultures | AMGEN INC. (US) | 2022-07-12 | — | — | US | disclosed |
| US-20220175758-A1 | COMPOSITIONS AND METHODS TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASES (NAFLD) | Coherus Biosciences, Inc. | 2022-06-09 | — | — | US | disclosed |
| US-20220177841-A1 | EX VIVO METHODS FOR PRODUCING A T CELL THERAPEUTIC AND RELATED COMPOSITIONS AND METHODS | MYST THERAPEUTICS LLC (US) | 2022-06-09 | — | — | US | disclosed |
| WO-2022115641-A2 | ANTIGEN SPECIFIC T CELLS AND METHODS OF MAKING AND USING SAME | GENEIUS BIOTECHNOLOGY, INC. (US) | 2022-06-02 | — | — | WO | disclosed |
| US-20220136025-A1 | METHODS FOR HARVESTING MAMMALIAN CELL CULTURES | AMGEN INC. (US) | 2022-05-05 | — | — | US | disclosed |
| CN-114269370-A | Methods of ex vivo production of T cell therapeutics and related compositions and methods | 迈斯特治疗公司 | 2022-04-01 | — | — | CN | disclosed |
| EP-3946437-A1 | EX VIVO METHODS FOR PRODUCING A T CELL THERAPEUTIC AND RELATED COMPOSITIONS AND METHODS | Myst Therapeutics, LLC (US) | 2022-02-09 | — | — | EP | disclosed |
| US-20210076956-A1 | Methods and Compositions for Restoring Homeostatic Capacity of a Subject | Palo Alto Investors LP | 2021-03-18 | — | — | US | disclosed |
| US-10835134-B2 | Methods and compositions for restoring homeostatic capacity of a subject | PALO ALTO INVESTORS (US) | 2020-11-17 | — | — | US | disclosed |
| WO-2020205023-A1 | COMPOSITIONS AND METHODS TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASES (NAFLD) | Coherus Biosciences, Inc. (US) | 2020-10-08 | — | — | WO | disclosed |
| US-20150359888-A1 | Methods and Compositions for Restoring Homeostatic Capacity of a Subject | PALO ALTO INVESTORS | 2015-12-17 | — | — | US | disclosed |
| WO-2013089819-A2 | MICRORNA MEDIATED NEURONAL CELL INDUCTION | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2013-06-20 | — | — | WO | disclosed |
| US-20120277111-A1 | MicroRNA Mediated Neuronal Cell Induction | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2012-11-01 | — | — | US | disclosed |
| US-7521480-B2 | Aryl ureido benzoic acid derivatives and their use | NEUROSEARCH (DK) | 2009-04-21 | — | — | US | disclosed |
| US-20060069255-A1 | Novel aryl ureido benzoic acid derivatives and their use | NEUROSEARCH (DK) | 2006-03-30 | — | — | US | disclosed |
| EP-1565429-A2 | ARYL UREIDO DERIVATIVES AND THEIR MEDICAL USE | NEUROSEARCH A/S (DK) | 2005-08-24 | — | — | EP | disclosed |
| US-20050080112-A1 | Compounds for use in disorders associated with mast cell or basophil acitvity | POSEIDON PHARMACEUTICALS A/S (DK) | 2005-04-14 | — | — | US | disclosed |
| WO-2004046090-A2 | ARYL UREIDO DERIVATIVES AND THEIR MEDICAL USE | NEUROSEARCH A/S (DK) | 2004-06-03 | — | — | WO | disclosed |
| US-20040077634-A1 | Treatment of diseases characterized by excessive or insufficient cell death | NEUROSEARCH A/S (DK) | 2004-04-22 | — | — | US | disclosed |
| US-20040077634-A1 | Treatment of diseases characterized by excessive or insufficient cell death | NEUROSEARCH A/S (DK) | 2004-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220175758-A1 | COMPOSITIONS AND METHODS TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASES (NAFLD) | SLC10A1, LIPC, FABP1 | GRIK1 1516/4885MEN1 4105/4885KMT2A 2947/4885 |
| US-20040077634-A1 | Treatment of diseases characterized by excessive or insufficient cell death | APAF1, CASP9, AIFM1 | GRIK1 2784/4885MEN1 2620/4885KMT2A 3856/4885 |
| US-20060069255-A1 | Novel aryl ureido benzoic acid derivatives and their use | GABRA5, GRIK5, GRM5 | GRIK1 24/4885MEN1 4843/4885KMT2A 2063/4885 |
| US-20050080112-A1 | Compounds for use in disorders associated with mast cell or basophil acitvity | CPA3, HNMT, CMA1 | GRIK1 655/4885MEN1 903/4885KMT2A 1345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.